Keyword: Celldex Therapeutics

After PhIII brain cancer vax bust, Celldex looks outward with Kolltan buy

Just eight months ago, small-cap Celldex Therapeutics saw its shares plunge by two-thirds after its brain cancer vax Rintega (rindopepimut) failed to improve overall survival in a key late-stage test. Today, it is brushing off that hit with the acquisition of Kolltan Pharmaceuticals to bolster its pipeline.